Vasopressin for Vasoplegic Shock Market Overview 2030
Vasopressin is a peptide hormone used to increase blood pressure levels in patients with vasoplegic shocks that occur post cardiac surgeries. Vasopressin is a drug used for treatment of diabetes insipidus, which is caused due to absence of pituitary hormone in the body. In clinical models of cardiac arrests and related syndromes, vasopressin pumps blood in the heart and brain, thus improving long-term survival chances. Apart from this, vasopressin finds application in the treatment of gastro intestinal bleeding and ventricular defibrillation. Various conducted trials have shown that infusion of vasopressin to such patients increases the systemic vascular resistance levels against vasoplegic shocks. Vasopressin increases the arterial pressure in patients, thus providing better survival chances.
Vasoplegic is a pathological syndrome exhibiting low vascular resistance. This further leads to reduced blood pressure levels. Additionally, one of the possible outcomes of COVID-19 pandemic include cardiac syndromes risks, thus pushing for enhanced demand for vasopressin drugs. The global pharmaceutical players are eyeing higher investments to develop advanced vasopressin. This includes market strategies such as collaborations, acquisitions, and mergers in an attempt to gain significant competitive edge over competitors during the forecasted period. Additionally, companies are looking at higher brand reputation in the market place by achieving cost leadership through manufacturing the drug at cheaper rates and selling them through effective and efficient distribution channel system, making use of agile techniques.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the vasopressin for vasoplegic market.
Top Impacting Factors
Growing concern of cardiac related syndromes in COVID-19 patients is bound to increase sales of vasopressin.
The ever-increasing growth of pilot studies in the sphere of appraising efficacy of vasopressin against vasoplegic shocks provides a strong case for two-fold market expansion.
Increasing numbers of cardiac surgeries especially in Asia-Pacific is a factor leading to exponential demand for this drug. As per the reports of the North American Cardiac Surgery Working Group, a total of 60,452 cardiac surgeries were performed in 2019 alone .
Countries with higher ageing populations such as China and India are at higher risk of sepsis incidences, thus stimulating the growth of vasopressin.
However, higher intake of vasopressin may lead to higher water levels in kidney leading to unbalanced antidiuretic hormone secretion (ADH), which might act as a restraining factor for the market.
Key Market Trends
Increase in cases of sepsis in North America is expected to offer remunerative opportunities for the market expansion in the region.
Similarly, encouraging government policies all across Europe coupled with steady private sector investments in the sector boost the growth of the vasopressin market across the continent.
Third world economies, such as India, are witnessing exponential rise in vasopressin for vasoplegic shock market, owing to tier-2 and tier-3 independent manufacturers entering the market against global players.
The latest surviving sepsis campaign guidelines now consider that the best therapeutic management of vasoplegic shocks include a multimodal approach consisting of several vasopressors consisting of early prescription of vasopressin coupled with norepinephrine.
In the latest VANISH study, terlipressin, a vasopressin analog with V1 receptor activity has been proposed as the second line of defense against vasoplegic shocks. However, early clinical trials showcase that terlipressin is not shown to offer a greater advantage over vasopressin, due to its longer half-life, thus, two novel potential drugs namely selepressin and angiotensin II are being accessed instead.
Key Benefits of the Report
- This study presents the analytical depiction of the vasopressin for vasoplegic shock market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the vasopressin for vasoplegic shock market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Adenovirus Diagnostic Testing Report
- Which are the leading players active in the vasopressin for vasoplegic shock market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the vasopressin for vasoplegic shock market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is vasopressin for vasoplegic shock market?
Vasopressin for Vasoplegic Shock Market, by Type Report Highlights
| Aspects | Details |
 By Type |
|
 By Applications |
|
 By Region |
|
 Key Market Players | ENDO International, Avadel, Astellas Pharma, Novartis AG, Sanofi, Ferring B.V., La Jolla Pharmaceuticals, AMOMED Pharma, Pfizer, CSL Limited |
Loading Table Of Content...
